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Abstract
Background Recent evidence suggests a role for progesterone
in breast cancer development and tumorigenesis. Progesterone
exerts its effect on target cells by interacting with its receptor;
thus, genetic variations, which might cause alterations in the
biological function in the progesterone receptor (PGR), can
potentially contribute to an individual's susceptibility to breast
cancer. It has been reported that the PROGINS allele, which is
in complete linkage disequilibrium with a missense substitution
in exon 4 (G/T, valine→leucine, at codon 660), is associated
with a decreased risk for breast cancer.
Methods Using a nested case-control study design within the
Nurses' Health Study cohort, we genotyped 1252 cases and
1660 matched controls with the use of the Taqman assay.
Results We did not observe any association of breast cancer
risk with carrying the G/T (Val660→Leu) polymorphism (odds
ratio 1.10, 95% confidence interval 0.93–1.30). In addition, we
did not observe an interaction between this allele and
menopausal status and family history of breast cancer as
reported previously.
Conclusion Overall, our study does not support an association
between the Val660→Leu PROGINS polymorphism and breast
cancer risk.
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Introduction
Until recently, the role of progesterone on mammary gland
tumorigenesis was not well understood. Data from epide-
miological studies revealed a higher risk for breast cancer
in postmenopausal women who used a combination of
estrogens and progestins, in comparison with those
women who used estrogens alone [1,2]. As demonstrated
in the progesterone receptor knockout mouse, the physio-
logical effects of progesterone are completely dependent
on the presence of its receptor gene, PGR, which exists as
a single-copy gene. The PGR gene uses separate promot-
ers and translational start sites to produce two protein iso-
forms, hPR-A and hPR-B [3-5], that are identical except for
an additional 165 amino acids present only in the amino ter-
minus of hPR-B [6,7]. Although hPR-B shares many impor-
tant structural domains with hPR-A, the two isoforms are
functionally distinct transcription factors [8] that mediate
their own response genes and physiological effects with lit-
tle overlap [9,10]. The progesterone receptor knockout
mouse, in which the functional activity of both hPR-A and
hPR-B were simultaneously ablated, revealed that proges-
terone is required for the formation of ductal and alveolar
structures during pregnancy [11,12]. Selective ablation of
PR-B in a mouse model, resulting in the exclusive produc-
tion of PR-A, revealed that PR-B is necessary for breast for-
mation [13]. Given the evidence described above for the
role of progesterone in breast cancer causation, we pro-
posed that variations in the PGR gene might predispose
women to breast cancer. Several studies have investigated
the Val660 →Leu G/T polymorphism and the PROGINS
Alu insertion, which are in complete linkage disequilibrium
[14], in association with breast cancer [15-17]. In this
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study we focused on the Val660→Leu G/T polymorphism
that has been reported to be associated with a decreased
risk of breast cancer [17].
Materials and methods
Detailed information about this nested case-control study
and exposure data has been reported previously [18]. The
protocol was approved by the Committee on Human Sub-
jects, Brigham and Women's Hospital. Genotyping assays
were performed by the 5' nuclease assay (TaqMan®) by the
ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA). TaqMan primers, probes,
and conditions for genotyping assays are available from the
authors on request. Genotyping was performed by labora-
tory personnel blinded to case-control status, and blinded
quality control samples were inserted to validate genotyp-
ing procedures. Concordance for the blinded samples was
100%.
Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated by using conditional and unconditional
logistic regression. In addition to the matching variables,
we adjusted for breast cancer risk factors: body mass index
(BMI) (kg/m2) at age 18 years, weight gain since age 18
years, age at menarche, parity/age at first birth, duration of
postmenopausal hormone use, first-degree family history of
breast cancer, and history of benign breast disease. We
also adjusted for age at menopause in analyses limited to
postmenopausal women. Indicator variables for all geno-
types were created by using the wild-type genotype as the
reference category in the regression models. Because of
the low prevalence of homozygous variants, we combined
heterozygotes and homozygotes in the logistic regression
analysis. Interactions between genotypes and breast can-
cer risk factors were evaluated by including appropriate
interaction terms in unconditional logistic regression mod-
els. The nominal likelihood ratio test was used to assess the
statistical significance of these interactions. We used SAS
version 8.0 (SAS Institute, Cary, NC) for all analyses. We
tested Hardy–Weinberg agreement by using a χ2 test.
Results and discussion
Our study included a total of 1323 incident breast cancer
cases, diagnosed after blood draw to 1 June 2000, and
1854 matched controls. Of these, 1134 cases and 1640
controls were postmenopausal at blood draw, and 112
cases and 121 controls were premenopausal; menopausal
status was uncertain in 77 cases and 93 controls. The
mean age of cases at blood draw was 57.3 years; for con-
trols it was 57.9 years. Cases and controls had similar
mean BMI at blood draw (25.5 versus 25.5 kg/m2) and
weight gain since age 18 years (11.6 versus 11.3 kg). In
comparison with controls, cases had similar ages at
menarche (12.5 versus 12.6 years), first birth (23.0 versus
23.0 years) and age at menopause (48.2 versus 47.9
years). The proportion of women with a first-degree family
history of breast cancer was significantly higher among the
cases (20.0% versus 15.0%). Cases were also more likely
to have a history of benign breast disease (64.0% versus
51.0%) and a longer duration of postmenopausal hormone
use (50.3% versus 49.7% current users for five or more
years). The study population was predominantly Caucasian
(89% of cases, 86% of controls).
The prevalence of the variant carriers was similar to that in
a previous report for Caucasian women [14]: 31% for the
cases and 29% for the controls. The genotype distribution
of the Val660→Leu polymorphism among the cases and
controls was in Hardy–Weinberg equilibrium. We did not
observe a statistically significant association of breast can-
cer among carriers of the Val660→Leu G/T polymorphism.
Too few homozygote variants were available in which to
analyze the heterozygotes and homozygotes separately.
Compared with the G/G wild-type genotype, the adjusted
OR for women with G/T and T/T was 1.10 (95% CI 0.93–
1.30) (Table 1). Because the previously reported inverse
association was confined to premenopausal women, we
stratified by menopausal status and observed no associa-
tion among premenopausal women (adjusted OR 1.21
[95% CI 0.64–2.28]) although we had a relatively small
number of women for this analysis (Table 1). The
Val660→Leu polymorphism has been suggested to modify
the association between family history of breast cancer and
breast cancer [17]. We observed no statistically significant
interactions between the Val660→Leu polymorphism and
first-degree family history of breast cancer. In addition, we
selected BMI, history of benign breast disease, and hor-
mone replacement therapy use among postmenopausal
women as potential effect modifiers based on biological
plausibility. We observed no significant interactions
between the Val660→Leu polymorphism and any of these
risk factors.
Conclusions
Our data do not support an inverse association between
the Val660→Leu polymorphism and breast cancer risk as
reported previously [17]. These results are consistent with
recent studies of mostly Caucasian women in which no
association was observed between this polymorphism and
breast cancer risk in either premenopausal or postmeno-
pausal women [15,16,19,20]. Most notable was the study
by Spurdle and colleagues, in which a substantial number
of premenopausal cases (n = 769) were evaluated [19].
We had limited power to study this association in premen-
opausal women, but this is the largest study of postmeno-
pausal women reported so far. The large sample size,
prospective design and extensive relevant life-style informa-
tion are among the strengths of this study. In conclusion,
our results suggest that there is no association between
the Val660→Leu polymorphism and breast cancer riskAvailable online http://breast-cancer-research.com/content/6/6/R636
R638
despite the substantial power of the study (more than 80%
p o w e r  t o  d e t e c t  a n  O R  o f  0 . 7 5  o r  l e s s  f o r  t h e  c a r r i e r
genotype).
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Association between the progesterone receptor exon 4 (Val660→Leu) G/T polymorphism and breast cancer risk
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at blood draw, time at blood draw, and fasting status.
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